Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012

Vaccine

Volumn 33, Issue 2, 2015, Pages 359-366

  Lepoutre, A ^a   Varon, E ^b   Georges, S ^a   Dorleans F ^a   Janoir, C ^b,c   Gutmann, L ^b   Levy Bruhl D ^a  

^a INSTITUT DE VEILLE SANITAIRE   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

France; Invasive pneumococcal disease; Pneumococcal conjugate vaccines; Population surveillance; Serotype replacement; Vaccine impact

Indexed keywords

PNEUMOCOCCUS VACCINE; PREVENAR13; VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; FRANCE; GROUPS BY AGE; HUMAN; IMMUNIZATION; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; NEWBORN; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROTYPE; VACCINATION; AGED; EPIDEMIOLOGY; FEMALE; HEALTH SURVEY; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; SEROTYPING; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; FRANCE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; SEROGROUP; SEROTYPING; TIME FACTORS; VACCINATION; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84922434125     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.11.011     Document Type: Article

References (29)

1. Cohen R., Gaudelus J., Pexoito O. Vaccin antipneumococcique conjugué: estimation de la population cible. Enquête auprès de 1739 mères. Méd enfance 2005, 25(4):237-242.
2. Lepoutre A., Varon E., Georges S., Gutmann L., Levy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill 2008, 13(35):18962.
3. Fonteneau L., Guthmann J.P., Levy-Bruhl D. Estimation of vaccination coverage in France through the Permanent Beneficiaries Sample (EGB): example of measles, hepatitis B and human papillomavirus vaccination. Bull Epidemiol Hebd 2013, 8-9:72-76.
4. De Roquefeuille L., Studer A., Neumann A., Merlière Y. The Echantillon généraliste de bénéficiaires: representativeness, scope and limits [L'échantillon généraliste de bénéficiaires: représentativité, portée et limites] 2009, 40 (3):213-223. Available at: www.cairn.info/revue-pratiques-et-organisation-des-soins-2009-3-page-213.htm (accessed 08.10.14). 10.3917/pos.403.0213.
5. Georges S., Lepoutre A., Dabernat H., Levy-Bruhl D. Impact of Haemophilus influenzae type b vaccination on the incidence of invasive Haemophilus influenzae disease in France, 15 years after its introduction. Epidemiol Infect 2013, 1-10.
6. Varon E., Janoir C., Gutmann L. Centre National de Référence des Pneumocoques: rapport d'activité 2013, Épidémiologie 2012, Available at: http://cnr-pneumo.fr/docs/rapports/CNRP2013.pdf (accessed 08.07.14).
7. Lepoutre A., Doloy A., Bidet P., Leblond A., Perrocheau A., Bingen E., et al. Epidemiology of invasive Streptococcus pyogenes infections in France in 2007. J Clin Microbiol 2011, 49(12):4094-4100.
8. Bingen E., Levy C., De la Roche F., Boucherat M., Varon E., Alonso J.M., et al. Bacterial meningitis in children: a French prospective study. Clin Infect Dis 2005, 41(7):1059-1063.
9. Guevara M., Barricarte A., Gil-Setas A., Garcia-Irure J.J., Beristain X., Torroba L., et al. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect 2009, 15(11):1013-1019.
10. Hanquet G., Kissling E., Fenoll A., George R., Lepoutre A., Lernout T., et al. Pneumococcal serotypes in children in 4 European countries. Emerg Infect Dis 2010, 16(9):1428-1439.
11. Munoz-Almagro C., Jordan I., Gene A., Latorre C., Garcia-Garcia J.J., Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008, 46(2):174-182.
12. Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 378(9807):1962-1973.
13. Feikin D.R., Kagucia E.W., Loo J.D., Link-Gelles R., Puhan M.A., Cherian T., et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med 2013, 10(9):e1001517.
14. Vestrheim D.F., Lovoll O., Aaberge I.S., Caugant D.A., Hoiby E.A., Bakke H., et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 2008, 26(26):3277-3281.
15. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(1):32-41.
16. Andrews N.J., Waight P.A., Burbidge P., Pearce E., Roalfe L., Zancolli M., et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis 2014, 14(9):839-846.
17. Angoulvant F., Levy C., Grimprel E., Varon E., Lorrot M., Biscardi S., et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis 2014, 58(7):918-924.
18. Guevara M., Ezpeleta C., Gil-Setas A., Torroba L., Beristain X., Aguinaga A., et al. Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001-2013. Vaccine 2014, 32(22):2553-2562.
19. Moore C.E., Paul J., Foster D., Mahar S.A., Griffiths D., Knox K., et al. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire Region of England. J Infect Dis 2014, 210(7):1001-1011. 10.1093/infdis/jiu213.
20. Picazo J., Ruiz-Contreras J., Casado-Flores J., Giangaspro E., Garcia-de-Miguel M., Hernandez-Sampelayo T., et al. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011. Pediatr Infect Dis J 2013, 32(6):656-661.
21. Steens A., Bergsaker M.A., Fau-Aaberge I., Aaberge I.S., Fau-Ronning K., Ronning K.F., et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013, 31(52):6232-6238.
22. Kaplan S.L., Barson W.J., Lin P.L., Romero J.R., Bradley J.S., Tan T.Q., et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013, 32(3):203-207.
23. Simonsen L., Taylor R.J., Schuck-Paim C., Lustig R., Haber M., Klugman K.P. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med 2014, 2(5):387-394.
24. Cohen R., Levy C., Bingen E., Koskas M., Nave I., Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012, 31(3):297-301.
25. Berger F., Parent du Châtelet I., Bernillon P., Gallay A. Surveillance des infections invasives à méningocoque en France métropolitaine en 2005. Évaluation quantitative par la méthode de capture-recapture à trois sources 2010, Institut de veille sanitaire, Saint-Maurice, 43 pp. Available at: http://opac.invs.sante.fr/index.php?lvl=notice:display&id=467 (accessed 08.07.14).
26. Perrocheau A. Evaluation de la surveillance des infections à méningocoques en France en 1996 par la méthode capture-recapture 2001, Institut de veille sanitaire, Saint-Maurice, 41 pp. Available at: http://opac.invs.sante.fr/index.php?lvl=notice:display&id=6073 (accessed 08.04.14).
27. Perrocheau A., Doyle A., Bernillon P., Varon E., le groupe des Observatoires Régionaux du Pneumocoque, De la Roche F., et al. Estimation du nombre total de méningites à pneumocoque de l'enfant par la méthode capture-recapture à 3 sources, France, 2001-2002. Bull Epidemiol Hebd 2006, 2-3:16-18. Available at: http://opac.invs.sante.fr/index.php?lvl=notice:display&id=5311 (accessed 08.07.14).
28. Harboe Z.B., Benfield T.L., Valentiner-Branth P., Hjuler T., Lambertsen L., Kaltoft M., et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 2010, 50(3):329-337.
29. Sabuncu E., David J., Bernede-Bauduin C., Pepin S., Leroy M., Boelle P.Y., et al. Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007. PLoS Med 2009, 6(6):e1000084. 10.1371/journal.pmed.1000084.